Table 4.

List of the most common adverse events reported in published phase 3 clinical trials in geographic atrophy in the study treatment arms of each study. For trials with more than one active treatment arm, the results from the two dosing regimens or drug concentrations are pooled.

	GATHER1	DERBY/OAKS *	CHROMA/SPECTRI	SEATTLE	GATE
Ocular	Conj. hemo. (24.7%) eAMD (9.3%) Increased IOP (6.7%)	eAMD (9.4%) ** IOI (3%) Endophthalmitis (1.2%)	Conj. hemo. (29.6%) Increased IOP (11.3%) Eye pain (10%)	Delayed DA (55.4%) Chromatopsia (17.6%) Visual impairment (15.4%)	Reduced VA (32.1%) Eye irritation (9.1%) Cataract (8.1%)
Non-ocular	UTI (9.3%) Fall (6.7%) Nasoph. (6%)	Not reported	URTI (8.6%) Fall 8.6%) Bronchitis (5.5%)	Fall (9.7%) Nasoph. (9.2%) Hypertension (9.6%)	Not reported

Conj. hemo.: conjunctival hemorrhage; DA: dark adaptation; eAMD: exudative age-related macular degeneration; IOI: intraocular inflammation; IOP: intraocular pressure; nasoph: nasopharyngitis; URTI: upper respiratory tract infection; UTI: urinary tract infection; VA: visual acuity. * Pending detailed reporting; ** As determined by the investigator.